Pharma BD Deal Intelligence
Horizon Pharma plc / Crealta Holdings LLC
2016 · Acquisition/Merger · $510M · Complete
Announcement Sentiment
50
Neutral / mixed
Horizon Pharma completed acquisition of Crealta Holdings for ~$510M cash, gaining marketed products KRYSTEXXA (pegloticase, for chronic refractory gout) and MIGERGOT. Crealta became Horizon Pharma Rheumatology LLC. Builds Horizon's rare-disease/specialty pharma platform.
Did it work? Outcome assessment
Strategic verdict
Achieved Stated Rationale
Financial impact
Accretive
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
- Announced Jan 13, 2016
- Closed Jan 13, 2016
- Deal value $510M
- Deal type Acquisition/Merger
- Therapeutic area Chronic refractory gout (KRYSTEXXA); migraine (MIGERGOT)
- Indications Chronic refractory gout (KRYSTEXXA); migraine (MIGERGOT)
- Key assets KRYSTEXXA (pegloticase); MIGERGOT
- Mechanism PEGylated uricase enzyme (KRYSTEXXA)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals